Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.36 |
| ▸ | SQLE | Q14534 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7704822 | 0.89 | CHRNB2 (0.43) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7704824 | 0.89 | CHRNB2 (0.43) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7708146 | 0.89 | CHRNB2 (0.43) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6820912 | 0.88 | KMT2A (0.55) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL6820914 | 0.88 | KMT2A (0.55) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL7710789 | 0.87 | CHRNB2 (0.40) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7708096 | 0.87 | CHRNB2 (0.40) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7708094 | 0.87 | CHRNB2 (0.40) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20414120 | 0.86 | KMT2A (0.52) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL11548660 | 0.86 | KMT2A (0.52) | KMT2AMAPTALDH1A1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732062-B2 | Modification polymerization initiator and method for preparing the same | LG CHEM, LTD. | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732062-B2 | Modification polymerization initiator and method for preparing the same | TET1, DNMT1, MAT1A | KMT2A 1054/4885CHRNB2 4714/4885CHRNB4 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.